[ad_1]
The Reno-based neuro-pharmaceutical firm’s microdosing division is expanding its slate of research and clinical trials
Mind Medicine (MindMed) Inc (NEO:MMED) () said it had appointed a world-leading psychedelics researcher as principal investigator for the first ever Phase 2a proof-of-concept clinical trial assessing lysergic acid diethylamide (LSD) to treat attention deficit hyperactivity disorder (ADHD) in adults.
It comes as the Reno-based neuro-pharmaceutical firm’s microdosing division, which is assessing consuming very low, sub-hallucinogenic doses of psychedelic ...